July 14, 2025 · Form 4 insider transaction
Krishnan Suma sold 13,335 shares of Krystal Biotech, Inc. at $150.29 per share, a transaction worth $2.00M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.; The transaction was executed in multiple trades ranging from $150.00 to $150.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.